Back to top
more

UnitedHealth Group (UNH)

(Delayed Data from NYSE)

$577.96 USD

577.96
3,124,914

-11.18 (-1.90%)

Updated Sep 17, 2024 04:00 PM ET

After-Market: $578.01 +0.05 (0.01%) 5:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 28% (181 out of 251)

Industry: Medical - HMOs

Better trading starts here.

Zacks News

UnitedHealth Group, Inc. is the largest health care services company in the world, serving over 50 million individuals in the United States as of 2019 and over 5 million internationally. The company provides a wide range of health care products and services, such as health maintenance organizations (HMOs), point of service plans (POS), preferred provider organizations (PPOs), and managed fee-for-service programs. UnitedHealth has the largest and most diverse membership base within the managed-care organization market, which gives it significant competitive advantages. It also has built its prescription drug business through OptumRx division, with the acquisition of Catamaran in 2015.

AMN Healthcare (AMN) Q1 Earnings, Revenues Beat Estimates

AMN Healthcare's (AMN) robust Q1 results demonstrate its segmental strength.

John Blank headshot

A Return to Fundamentals: Zacks May 2022 Strategy

With the YTD return for the S&P 500 down -13.0% to May 5th, I think you might be surprised by the following simple math exercise. Pleasantly surprised.

McKesson (MCK) Q4 Earnings Miss, Revenues Beat Estimates

McKesson's (MCK) fiscal fourth-quarter 2022 results benefit from segmental growth.

Inari Medical (NARI) Down 16.9% Despite Q1 Earnings Beat

Inari Medical's (NARI) first-quarter results benefit from significant progress made across all of its growth drivers.

Myriad Genetics (MYGN) Reports Loss in Q1, Gross Margin Down

Myriad Genetics' (MYGN) sales in the majority of the operating segments improved in the first quarter despite a challenging business environment.

Illumina (ILMN) Q1 Earnings Beat Estimates, Gross Margin Down

Illumina (ILMN) ended the first quarter with better-than-expected earnings and revenues on strength in Core Illumina and the GRAIL businesses driving the top line.

Avanos Medical (AVNS) Q1 Earnings, Revenues Top Estimates

Avanos Medical's (AVNS) first-quarter 2022 results reflect strength in the Pain Management segment.

Phibro (PAHC) Q3 Earnings Lag Estimates, 2022 Revenue View Up

In Q3, Phirbo (PAHC) reports growth in the Animal Health business on higher sales of processing aids, which are used to improve production efficiency in the ethanol fermentation industry.

DaVita (DVA) Misses on Q1 Earnings, Reiterates FY22 EPS View

Despite strength in dialysis patient service revenues, DaVita (DVA) records an overall soft Q1 performance.

Quidel (QDEL) Q1 Earnings, Revenues Surpass Estimates, Up Y/Y

Quidel's (QDEL) robust performance across two of its product categories drives its first-quarter 2022 top line.

CONMED's (CNMD) Q1 Earnings and Revenues Surpass Estimates

CONMED's (CNMD) first-quarter earnings reflect strong segmental performance.

PacBio's (PACB) Q1 Earnings Miss Estimates, Revenues Beat

PacBio (PACB) sees strength in Q1 segmental revenues, led by robust consumable and instrument sales.

LHC Group (LHCG) Q1 Earnings Beat Estimates, Revenues Miss

LHC Group's (LHCG) first-quarter results benefit from organic growth in both home health as well as hospice admissions.

Cardinal Health (CAH) Q3 Earnings Lag Estimates, Revenues Top

Cardinal Health's (CAH) fiscal third-quarter results benefit from a solid performance in the Pharmaceutical segment.

BD (BDX) Beats on Q2 Earnings and Revenues, Revises FY22 View

The majority of BD's (BDX) core units witness strong revenue growth in the fiscal second quarter.

Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Up

Revenue growth across the BSI and BEST businesses drove Bruker's (BRKR) first-quarter 2022 revenues.

Tandem Diabetes (TNDM) Q1 Earnings Lag Estimates, Sales View Up

Robust pump shipments and growth in the installed customer base are driving Tandem Diabetes' (TNDM) first-quarter top line.

Cardiovascular Systems' (CSII) Q3 Earnings Top Estimates

Cardiovascular Systems' (CSII) third-quarter revenues declined year over year due to lower Coronary and peripheral revenues.

NuVasive (NUVA) Q1 Earnings Beat Estimates, 2022 View Up

Robust sales performance across all U.S. product lines drove NuVasive's (NUVA) Q1 top line.

Charles River (CRL) Q1 Earnings Top, Gross Margin Falls

Charles River (CRL) Q1 results highlight 9.8% organic revenue growth, driven by strength across all three segments.

CVS Health (CVS) Q1 Earnings Top Estimates, '22 EPS View Up

CVS Health (CVS) reports better-than-expected results for Q1, with robust segmental performance driving the top line.

Masimo's (MASI) Q1 Earnings Surpass Estimates, FY22 View Up

Masimo's (MASI) robust product shipments drive its Q1 sales.

Cerner (CERN) Q1 Earnings in Line, Revenues Lag Estimates

Cerner's (CERN) first-quarter results benefit from gains across four of its business units.

PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates

PerkinElmer's (PKI) first-quarter results benefit from a solid performance at Discover & Analytics Solutions business.

IDEXX (IDXX) Q1 Earnings Surpass Estimates, Margins Down

Strong sales at the CAG and Water businesses drove IDEXX's (IDXX) first-quarter 2022 revenues.